Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene HRAS
Variant V29Cfs*19
Impact List frameshift
Protein Effect loss of function - predicted
Gene Variant Descriptions HRAS V29Cfs*19 indicates a shift in the reading frame starting at amino acid 29 and terminating 19 residues downstream causing a premature truncation of the 189 amino acid Hras protein (UniProt.org). Due to the loss of the GTP binding domain (UniProt.org), V29Cfs*19 is predicted to lead to a loss of Hras protein function resulting in inactivation of downstream signaling.
Associated Drug Resistance
Category Variants Paths

HRAS mutant HRAS inact mut HRAS V29Cfs*19

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005343.4
gDNA chr11:g.534242dupA
cDNA c.84dupT
Protein p.V29Cfs*19
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_005343.3 chr11:g.534242dupA c.84dupT p.V29Cfs*19 RefSeq GRCh38/hg38
NM_001130442 chr11:g.534239_534240insG c.83_84insC p.V29Cfs*19 RefSeq GRCh38/hg38
NM_005343.4 chr11:g.534242dupA c.84dupT p.V29Cfs*19 RefSeq GRCh38/hg38
NM_176795.4 chr11:g.534242dupA c.84dupT p.V29Cfs*19 RefSeq GRCh38/hg38
NM_001130442.3 chr11:g.534242dupA c.84dupT p.V29Cfs*19 RefSeq GRCh38/hg38
NM_176795 chr11:g.534239_534240insG c.83_84insC p.V29Cfs*19 RefSeq GRCh38/hg38
NM_005343 chr11:g.534239_534240insG c.83_84insC p.V29Cfs*19 RefSeq GRCh38/hg38
NM_176795.5 chr11:g.534242dupA c.84dupT p.V29Cfs*19 RefSeq GRCh38/hg38
NM_001130442.2 chr11:g.534242dupA c.84dupT p.V29Cfs*19 RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
HRAS V29Cfs*19 bladder urothelial carcinoma predicted - sensitive Tipifarnib Case Reports/Case Series Actionable In a Phase II trial, Zarnestra (tipifarnib) demonstrated manageable toxicity profile, resulted in an objective response rate of 33.3% (5/15) in patients with transitional cell carcinoma harboring HRAS mutations, a patient with bladder urothelial carcinoma harboring HRAS V29Cfs*19 achieved a partial response (PMID: 32636318; NCT02535650). 32636318